Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Ideaya Biosciences completes enrollment in OptimUM-02 trial
- Pfizer announces results from HER2CLIMB-05 trial
- Pfizer price target raised to $29 from $28 at HSBC
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk
- FDA probe into COVID vaccines includes adults, Bloomberg reports